Scarica l'app Stockscreener
18.69
5.03%
-0.99
Dopo l'orario di chiusura:
18.69
Precedente Chiudi:
$19.68
Aprire:
$19.85
Volume 24 ore:
433.07K
Relative Volume:
1.43
Capitalizzazione di mercato:
$1.75B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-9.88%
1M Prestazione:
-11.34%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$18.69
$20.04
Intervallo di 1 settimana:
$18.69
$22.05
Portata 52W:
$18.69
$27.00
Kardigan Inc Stock (KARD) Company Profile
Compare KARD vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KARD
Kardigan Inc
|
18.69 | 1.84B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kardigan Inc Borsa (KARD) Ultime notizie
Kardigan at Cantor conference: platform bet on heart drugs - Investing.com
Kardigan at Cantor conference: platform bet on heart drugs By Investing.com - Investing.com UK
KARDKardigan Inc Short Interest - Finviz
Kardigan to Present at Two September Investor Conferences - finance.yahoo.com
Kardigan’s Danicamtiv Heart Study Moves Forward, Keeping KARD on Investors’ Radar - TipRanks
Kardigan’s Tonlamarsen Trial Targets Severe Hypertension: What Investors Should Watch - TipRanks
KARD Should I Buy - Intellectia AI
Kardigan (NASDAQ:KARD) Price Target Cut to $46.00 by Analysts at JPMorgan Chase & Co. - marketbeat.com
Will KARD be a Portfolio Killer in August? - Zacks Investment Research
Inside cardiovascular biotech Kardigan’s June IPO - CFO Brew
Kardigan Q2 Results: EPS misses estimates by 549.3% - scanx.trade
Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates - BioSpace
Kardigan Inc. Announces Q2 2026 Financial Results and Clinical Trial Updates - Kalkine Media
Kardigan Q2 Per-Share Loss Narrows - marketscreener.com
Kardigan, Inc. 2Q 2026: Net loss $116.2M, EPS $(4.61) — 10-Q Summary - TradingView
Earnings Flash (KARD) Kardigan Posts Q2 Loss $4.61 a Share - marketscreener.com
Kardigan: Q2 Earnings Snapshot - AOL.com
Kardigan, Inc. (NASDAQ:KARD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Kardigan reports Q2 2026 net loss $116.2M, cash $660.7M after IPO - TradingView
Kardigan Ord Shs (KARD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kardigan (KARD) Institutional Ownership 2026 $KARD - marketbeat.com
KARD: NADetailed Earnings Estimates - Zacks Investment Research
KARD|Kardigan Ord Shs|Price:21.150|Chg%:+0.410 - TradingKey
Kardigan, Inc. Revenue Breakdown – NASDAQ:KARD - TradingView
Latest KARD ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
Kardigan, Inc. (KARD) stock price, news, quote and history - Yahoo Finance UK
Price to earnings ratio of Kardigan, Inc. – NASDAQ:KARD - TradingView
Price to earnings ratio of Kardigan, Inc. – BOATS:KARD - TradingView
Kardigan, Inc. (NASDAQ:KARD) Short Interest Up ∞ in June - MarketBeat
Hrtg Pv, L.p. Net Worth (2026) - GuruFocus
Kevin Anthony Kelly Net Worth (2026) - GuruFocus
Schf Cif 2024, L.p. Net Worth (2026) - GuruFocus
Keith Bryon Johnson Net Worth (2026) - GuruFocus
Kardigan, Inc.: Target Price Consensus and Analysts Recommendations | KARD | US4859251013 - marketscreener.com
Kardigan, Inc.: Revenue and Earnings Analysts Forecasts Revisions | KARD | US4859251013 - marketscreener.com
A Quick Look at Today's Ratings for Kardigan(KARD.US), With a Forecast Between $37 to $51 - Moomoo
Kardigan (KARD) grants 20,706 RSUs tied to Perceptive-linked director pay - Stock Titan
KARD Initiated Coverage by TD Cowen -- Price Target Announced at $46 - GuruFocus
KARD News & Events - Intellectia AI
TD Cowen initiates Kardigan stock with buy rating on cardiology pipeline - Investing.com UK
KARD Initiated Coverage by Leerink Partners -- Rating Outperform - GuruFocus
Kardigan (KARD) Stock Forecast and Price Target 2026 $KARD - MarketBeat
Jefferies initiates Kardigan stock with buy rating on cardiology pipeline By Investing.com - Investing.com Nigeria
KARD Initiated Coverage by JP Morgan -- Price Target Set at $51. - GuruFocus
This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Jefferies Initiates Kardigan at Buy With $40 Price Target - marketscreener.com
TD Cowen Initiates Kardigan(KARD.US) With Buy Rating, Announces Target Price $46 - Moomoo
TD Cowen initiates Kardigan stock with buy rating on cardiology pipeline By Investing.com - Investing.com India
JPMorgan initiates Kardigan stock with overweight on pipeline By Investing.com - Investing.com Nigeria
JPMorgan initiates Kardigan stock with overweight on pipeline - Investing.com UK
Jefferies initiates Kardigan stock with buy rating on cardiology pipeline - Investing.com
Kardigan Inc Azioni (KARD) Dati Finanziari
Non sono disponibili dati finanziari per Kardigan Inc (KARD). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):